
-
Ocugen NasdaqCM:OCGN Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Location: 11 Great Valley Parkway, Malvern, PA, 19355, United States | Website: https://www.ocugen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
215.5M
Cash
37.8M
Avg Qtr Burn
-12.73M
Short % of Float
23.74%
Insider Ownership
1.60%
Institutional Own.
26.46%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OCU400 Details Retinitis Pigmentosa | BLA Submission | |
NeoCart® (Autologous chondrocyte-derived neocartilage) Details Articular cartilage defects in the knee | Phase 3 Initiation | |
OCU410ST Details Stargardt disease, Rare genetic disease | Phase 2/3 Initiation | |
OCU410 Details Geographic atrophy, Age-related macular degeneration | Phase 1/2 Data readout | |
OCU400 Details Eye disease , Leber congenital amaurosis, Retinitis Pigmentosa | Phase 1/2 Data readout | |
OCU200 Details Diabetic macular edema | Phase 1 Data readout | |
OCU500 Details COVID-19 | Phase 1 Initiation | |
COVAXIN (BBV152) Details COVID-19, Infectious disease | Failed Discontinued |